Title: Safety and efficacy of weekly docetaxe in frail and/or elderly patients with metastatic breast cancer: a phase II study
Authors: D'hondt, Randal ×
Paridaens, Robert
Wildiers, Hans
Pauwelyn, Karen
Thomas, José
Dumez, Herlinde
Van Oosterom, Allan #
Issue Date: Apr-2004
Publisher: Lippincott williams & wilkins
Series Title: Anti-cancer drugs vol:15 issue:4 pages:341-346
Abstract: This phase 11 study was designed to evaluate the safety and efficacy of weekly docetaxel (36 mg/m(2)) for the treatment of metastatic breast cancer in 47 frail and/or elderly patients who were ineligible for the standard 3-weekly docetaxel (100 mg/m(2)) regimen. Reasons for ineligibility to the latter were age greater than or equal to 70 years (10 patients), poor hematological reserves (15 patients), impaired liver function (eight patients), intolerance to previous taxanes administered 3-weekly without demonstrated resistance (five patients) or any combination of these reasons (nine patients). There was a median of two prior chemotherapy regimens and more than 60% had a WHO performance score at baseline of 2-3. A total of 408 weekly administrations were given over a period of 525 weeks (78% of the intended dose intensity) and the median cumulative dose of docetaxel per patient was 278 mg/m(2). The incidence of serious adverse events was low. Grade 3 neutropenia occurred in six patients and grade 4 in four patients. Of these 10 patients, eight had pre-existing hematological abnormalities and four developed neutropenic fever. Neurotoxicity was mild and grade 3 paraesthesia occurred in one patient The overall objective response rate in 37 evaluable patients was 30% and responses were observed in all subgroups of patients. We conclude that weekly docetaxel (36 mg/m(2)) is active, safe and well tolerated in heavily pre-treated frail/elderly patients with poor prognostic features, including low performance scores and multiple metastatic sites, who would not be eligible for treatment with the standard 3-weekly regimen. (C) 2004 Lippincott Williams Wilkins.
ISSN: 0959-4973
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Laboratory of Experimental Oncology
Interdepartemental Stem Cell Institute (-)
Nuclear and Radiation Physics Section
Department of Oncology - miscellaneous
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science